{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:57:03Z","timestamp":1791593823460,"version":"4.3.4"},"reference-count":189,"publisher":"Elsevier","isbn-type":[{"value":"9780443429835","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.irn.2025.04.024","type":"book-chapter","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T08:33:19Z","timestamp":1753259599000},"page":"89-119","source":"Crossref","is-referenced-by-count":6,"title":["Autoantibodies in myasthenia gravis"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.irn.2025.04.024_bib1","article-title":"Myasthenia gravis and related disorders: Biochemical basis for disease of the neuromuscular junction. Key Biscayne FL, 29 May- 1","author":"Agius","year":"2002","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4158","key":"10.1016\/bs.irn.2025.04.024_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.186.4158.55","article-title":"Serum globulin in myasthenia gravis: Inhibition of alpha-bungarotoxin binding to acetylcholine receptors","volume":"186","author":"Almon","year":"1974","journal-title":"Science (New York, NY)"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib3","first-page":"289","article-title":"Relationship between anti-acetylcholine receptor antibody titres and severity of myasthenia gravis","volume":"59","author":"Aurangzeb","year":"2009","journal-title":"JPMA The Journal of the Pakistan Medical Association"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10072-024-07675-6","article-title":"AChR-seropositive myasthenia gravis in muscular dystrophy: Diagnostic pitfalls and clinical management challenges","volume":"46","author":"Avallone","year":"2025","journal-title":"Neurological Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CND.0b013e31824619d5","article-title":"The quantitative myasthenia gravis score: Comparison with clinical, electrophysiological, and laboratory markers","volume":"13","author":"Barnett","year":"2012","journal-title":"Journal of Clinical Neuromuscular Disease"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: Correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"issue":"6515","key":"10.1016\/bs.irn.2025.04.024_bib7","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4585","article-title":"Autoantibodies against type I IFNs in patients with life-threatening COVID-19","volume":"370","author":"Bastard","year":"2020","journal-title":"Science (New York, NY)"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib8","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/WNL.47.6.1552","article-title":"A transfected human muscle cell line expressing the adult subtype of the human muscle acetylcholine receptor for diagnostic assays in myasthenia gravis","volume":"47","author":"Beeson","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/pnp.738","article-title":"Changes in antibody titers and clinical course in myasthenia gravis retrospective study","volume":"26","author":"Berger","year":"2022","journal-title":"Progress in Neurology and Psychiatry"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: Long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/labmed\/lmy038","article-title":"A simple, rapid and non-radiolabeled immune assay to detect anti-AChR antibodies in myasthenia gravis","volume":"50","author":"Bokoliya","year":"2019","journal-title":"Laboratory Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib12","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1474-4422(23)00077-7","article-title":"Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): A randomised, double-blind, placebo-controlled, adaptive phase 3 study","volume":"22","author":"Bril","year":"2023","journal-title":"The Lancet Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib13","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/WNL.57.9.1579","article-title":"Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence?","volume":"57","author":"Buckley","year":"2001","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib14","article-title":"IgG1-3 MuSK antibodies inhibit AChR cluster formation, restored by SHP2 inhibitor, despite normal MuSK, DOK7, or AChR subunit phosphorylation","volume":"10","author":"Cao","year":"2023","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib15","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.immuni.2012.07.017","article-title":"Elimination of germinal-center-derived self-reactive B cells is governed by the location and concentration of self-antigen","volume":"37","author":"Chan","year":"2012","journal-title":"Immunity"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib16","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jns.2014.05.037","article-title":"Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population","volume":"343","author":"Chang","year":"2014","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib17","article-title":"Functional signature of LRP4 antibodies in myasthenia gravis","volume":"11","author":"Chuquisana","year":"2024","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib18","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1093\/brain\/awz106","article-title":"Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production","volume":"142","author":"Cotzomi","year":"2019","journal-title":"Brain"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib19","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/WNL.58.10.1563","article-title":"Myasthenia gravis in a woman with congenital AChR deficiency due to \u03b5-subunit mutations","volume":"58","author":"Croxen","year":"2002","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/jnnp-2022-329284","article-title":"Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis","volume":"93","author":"Damato","year":"2022","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.it.2019.01.005","article-title":"Role of IgG3 in infectious diseases","volume":"40","author":"Damelang","year":"2019","journal-title":"Trends in Immunology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib22","article-title":"The ligands for human IgG and their effector functions","volume":"8","author":"de Taeye","year":"2019","journal-title":"Antibodies (Basel)"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0960-8966(93)90027-H","article-title":"Arthrogryposis multiplex in a newborn of a myasthenic mother--case report and literature","volume":"3","author":"Dinger","year":"1993","journal-title":"Neuromuscular Disorders: NMD"},{"issue":"20","key":"10.1016\/bs.irn.2025.04.024_bib24","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"The New England Journal of Medicine"},{"issue":"1-3","key":"10.1016\/bs.irn.2025.04.024_bib25","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0022-1759(83)90069-8","article-title":"An enzyme-linked immunoabsorbent assay for measuring antibodies against muscle acetylcholine receptor","volume":"57","author":"Dwyer","year":"1983","journal-title":"Journal of Immunological Methods"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib26","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1113\/jphysiol.1964.sp007495","article-title":"An electrophysiological investigation of neuromuscular transmission in myasthenia gravis","volume":"174","author":"Elmqvist","year":"1964","journal-title":"The Journal of Physiology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib27","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: Ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clinic Proceedings. Mayo Clinic"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib28","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.29.2.179","article-title":"Passively transferred experimental autoimmune myasthenia gravis. Sequential and quantitative study of the motor end-plate fine structure and ultrastructural localization of immune complexes (IgG and C3), and of the acetylcholine receptor","volume":"29","author":"Engel","year":"1979","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib29","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti\u2010MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0896-8411(91)90017-7","article-title":"Anti-acetylcholine receptor antibodies in neonatal myasthenia gravis: Heterogeneity and pathogenic significance","volume":"4","author":"Eymard","year":"1991","journal-title":"Journal of Autoimmunity"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-022-01454-0","article-title":"Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy","volume":"10","author":"Fichtner","year":"2022","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/bs.irn.2025.04.024_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.024_bib33","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200513","article-title":"Affinity maturation is required for pathogenic monovalent IgG4 autoantibody development in myasthenia gravis","volume":"217","author":"Fichtner","year":"2020","journal-title":"Journal of Experimental Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib34","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/clinchem\/45.3.400","article-title":"TE671 cell-based ELISA for anti-acetylcholine receptor antibody determination in myasthenia gravis","volume":"45","author":"Franciotta","year":"1999","journal-title":"Clinical Chemistry"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib35","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.autrev.2014.08.039","article-title":"Cortactin autoantibodies in myasthenia gravis","volume":"13","author":"Gallardo","year":"2014","journal-title":"Autoimmunity Reviews"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.024_bib36","article-title":"Comparative analysis of BIOCHIP mosaic-based indirect immunofluorescence with enzyme-linked immunosorbent assay for diagnosing myasthenia gravis","volume":"11","author":"Gambino","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib37","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1365-2222.1997.tb00727.x","article-title":"The natural history of Apis-specific IgG and IgG4 in beekeepers","volume":"27","author":"Garcia-Robaina","year":"1997","journal-title":"Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology"},{"issue":"22","key":"10.1016\/bs.irn.2025.04.024_bib38","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1212\/WNL.0000000000000478","article-title":"Anti-agrin autoantibodies in myasthenia gravis","volume":"82","author":"Gasperi","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib39","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083924","article-title":"Stable expression of human muscle-specific kinase in HEp-2 M4 cells for automatic immunofluorescence diagnostics of myasthenia gravis","volume":"9","author":"George","year":"2014","journal-title":"PLoS ONE"},{"issue":"26","key":"10.1016\/bs.irn.2025.04.024_bib40","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib41","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nature Reviews. Neurology"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.024_bib42","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/art.40215","article-title":"Defective early B cell tolerance checkpoints in Sjogren\u2019s syndrome patients","volume":"69","author":"Glauzy","year":"2017","journal-title":"Arthritis & Rheumatology (Hoboken, NJ)"},{"issue":"5-6","key":"10.1016\/bs.irn.2025.04.024_bib43","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"issue":"6184","key":"10.1016\/bs.irn.2025.04.024_bib44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/334676a0","article-title":"Altered immunoglobulin expression and functional silencing of self- reactive B lymphocytes in transgenic mice","volume":"334","author":"Goodnow","year":"1988","journal-title":"Nature"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib45","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4049\/jimmunol.158.4.1919","article-title":"Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies","volume":"158","author":"Graus","year":"1997","journal-title":"Journal of Immunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib46","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/ni1076","article-title":"Receptor editing is the main mechanism of B cell tolerance toward membrane antigens","volume":"5","author":"Halverson","year":"2004","journal-title":"Nature Immunology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib47","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/clinchem\/39.10.2053","article-title":"Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis","volume":"39","author":"Hara","year":"1993","journal-title":"Clinical Chemistry"},{"key":"10.1016\/bs.irn.2025.04.024_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578063","article-title":"Caution on LRP4 antibody results in patients being evaluated for myasthenia gravis","volume":"377","author":"Heber","year":"2023","journal-title":"Journal of Neuroimmunology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib49","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/08916938809010682","article-title":"Epitopes on human acetylcholine receptor defined by monoclonal antibodies and myasthenia gravis sera","volume":"1","author":"Heidenreich","year":"1988","journal-title":"Autoimmunity"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.024_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0114060","article-title":"Repeated acetylcholine receptor antibody-concentrations and association to clinical myasthenia gravis development","volume":"9","author":"Heldal","year":"2014","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib51","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to Low-density lipoprotein-receptor related protein-4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0165-0270(83)90127-9","article-title":"An enzyme-linked immunosorbent assay for antibody against acetylcholine receptor","volume":"9","author":"Hinman","year":"1983","journal-title":"Journal of Neuroscience Methods"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib53","doi-asserted-by":"crossref","first-page":"909","DOI":"10.4049\/jimmunol.175.2.909","article-title":"In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance","volume":"175","author":"Hippen","year":"2005","journal-title":"Journal of Immunology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib54","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/2049-632X.12034","article-title":"IgG subclass profiles in normal human sera of antibodies specific to five kinds of microbial antigens","volume":"67","author":"Hjelholt","year":"2013","journal-title":"Pathogens and Disease"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nature Medicine"},{"key":"10.1016\/bs.irn.2025.04.024_bib56","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): A randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"The Lancet Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.024_bib58","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): A multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"The Lancet Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.024_bib59","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"The Lancet Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib60","article-title":"IgG-specific cell-based assay detects potentially pathogenic MuSK-Abs in seronegative MG","volume":"4","author":"Huda","year":"2017","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib61","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/mus.25154","article-title":"Characteristics of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort","volume":"54","author":"Huda","year":"2016","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib62","article-title":"MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity","volume":"6","author":"Huijbers","year":"2019","journal-title":"Neurology(R) Neuroimmunology & Neuroinflammation"},{"issue":"51","key":"10.1016\/bs.irn.2025.04.024_bib63","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib64","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","article-title":"Myasthenia gravis: The changing treatment landscape in the era of molecular therapies","volume":"20","author":"Iorio","year":"2024","journal-title":"Nature Reviews Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11882-016-0600-2","article-title":"Potential mechanisms for IgG4 inhibition of immediate hypersensitivity reactions","volume":"16","author":"James","year":"2016","journal-title":"Current Allergy and Asthma Reports"},{"key":"10.1016\/bs.irn.2025.04.024_bib66","series-title":"Immunobiology: The immune system in health and disease; chapter 8 the development of B and T lymphocytes","author":"Janeway","year":"2017"},{"key":"10.1016\/bs.irn.2025.04.024_bib67","series-title":"Immunobiology: The immune system in health and disease; chapter 4 antigen recognition by B-cell and T-cell receptors","author":"Janeway","year":"2017"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.024_bib68","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1073\/pnas.90.7.2895","article-title":"Muscle-specific trk-related receptor with a kringle domain defines a distinct class of receptor tyrosine kinases","volume":"90","author":"Jennings","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"48","key":"10.1016\/bs.irn.2025.04.024_bib69","doi-asserted-by":"crossref","first-page":"30649","DOI":"10.1073\/pnas.2007206117","article-title":"Thymus-derived B cell clones persist in the circulation after thymectomy in myasthenia gravis","volume":"117","author":"Jiang","year":"2020","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2025.04.024_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.886625","article-title":"Corticosteroid treatment-resistance in myasthenia gravis","volume":"13","author":"Kaminski","year":"2022","journal-title":"Frontiers in Neurology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib71","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jns.2014.12.015","article-title":"Collagen Q\u2013a potential target for autoantibodies in myasthenia gravis","volume":"348","author":"Katarzyna","year":"2015","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib72","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.410150214","article-title":"Enzyme-linked immunosorbent assay for antibody against the nicotinic acetylcholine receptor in human myasthenia gravis","volume":"15","author":"Kawanami","year":"1984","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2025.04.024_bib73","series-title":"StatPearls","article-title":"Thymic hyperplasia","author":"Khan","year":"2022"},{"key":"10.1016\/bs.irn.2025.04.024_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577895","article-title":"LRP4-IgG service line testing in seronegative myasthenia gravis and controls","volume":"368","author":"Klein","year":"2022","journal-title":"Journal of Neuroimmunology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib75","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.humimm.2013.06.020","article-title":"Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis","volume":"74","author":"Klein","year":"2013","journal-title":"Human Immunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib76","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jca.20317","article-title":"A randomized and controlled study comparing immunoadsorption and plasma exchange in myasthenic crisis","volume":"26","author":"K\u00f6hler","year":"2011","journal-title":"Journal of Clinical Apheresis"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib77","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1136\/jnnp-2020-325511","article-title":"Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome","volume":"92","author":"Kojima","year":"2021","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/bs.irn.2025.04.024_bib78","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2016.11.005","article-title":"IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients","volume":"77","author":"Koneczny","year":"2017","journal-title":"Journal of Autoimmunity"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib79","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jneuroim.2007.07.018","article-title":"Extracellular domains of the beta, gamma and epsilon subunits of the human acetylcholine receptor as immunoadsorbents for myasthenic autoantibodies: A combination of immunoadsorbents results in increased efficiency","volume":"190","author":"Kostelidou","year":"2007","journal-title":"Journal of Neuroimmunology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib80","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.nmd.2011.06.751","article-title":"Acetylcholine receptor antibodies in patients with genetic myopathies: Clinical and biological significance","volume":"22","author":"Lane","year":"2012","journal-title":"Neuromuscular Disorders"},{"key":"10.1016\/bs.irn.2025.04.024_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; Implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Frontiers in Immunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib82","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/acn3.311","article-title":"Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis","volume":"3","author":"Lee","year":"2016","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib83","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/jnnp.41.5.394","article-title":"Determination of acetylcholine receptor antibody in myasthenia gravis: Clinical usefulness and pathogenetic implications","volume":"41","author":"Lefvert","year":"1978","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0165-5728(81)90015-1","article-title":"Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis","volume":"1","author":"Lefvert","year":"1981","journal-title":"Journal of Neuroimmunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib85","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: Taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"Journal of Neurology"},{"issue":"20","key":"10.1016\/bs.irn.2025.04.024_bib86","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"issue":"Pt 7","key":"10.1016\/bs.irn.2025.04.024_bib87","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib88","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody\u2010positive than in MuSK antibody\u2010negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Annals of Neurology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.024_bib89","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.145.7.2115","article-title":"Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis","volume":"145","author":"Leprince","year":"1990","journal-title":"Journal of Immunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/clin.1996.0001","article-title":"The thymus and the pathogenesis of myasthenia gravis","volume":"78","author":"Levinson","year":"1996","journal-title":"Clinical Immunology and Immunopathology"},{"key":"10.1016\/bs.irn.2025.04.024_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanwpc.2023.100846","article-title":"A multicentre, prospective, double-blind study comparing the accuracy of autoantibody diagnostic assays in myasthenia gravis: The SCREAM study","volume":"38","author":"Li","year":"2023","journal-title":"The Lancet Regional Health. Western Pacific"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib92","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0090-1229(77)90027-7","article-title":"An assay for antibodies to human acetylcholine receptor in serum from patients with myasthenia gravis","volume":"7","author":"Lindstrom","year":"1977","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib93","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/jss.400040310","article-title":"Immunological studies of acetylcholine receptors","volume":"4","author":"Lindstrom","year":"1976","journal-title":"Journal of Supramolecular Structure"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.024_bib94","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib95","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor","volume":"22","author":"Loutrari","year":"1992","journal-title":"European Journal of Immunology"},{"key":"10.1016\/bs.irn.2025.04.024_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2024.113627","article-title":"Comparison of three methods for the detection of antibodies against muscle-specific kinase","volume":"526","author":"Luong","year":"2024","journal-title":"Journal of Immunological Methods"},{"key":"10.1016\/bs.irn.2025.04.024_bib97","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jneuroim.2019.04.001","article-title":"False-positive acetylcholine receptor antibody results in patients without myasthenia gravis","volume":"332","author":"Maddison","year":"2019","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/bs.irn.2025.04.024_bib98","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jaut.2017.05.005","article-title":"Methylome and transcriptome profiling in myasthenia gravis monozygotic twins","volume":"82","author":"Mamrut","year":"2017","journal-title":"Journal of Autoimmunity"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib99","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","article-title":"Post-intervention status in patients with refractory myasthenia gravis treated with eculizumab during REGAIN and its open-label extension","volume":"96","author":"Mantegazza","year":"2021","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.024_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135378","article-title":"Flow cytofluorimetric analysis of anti-LRP4 (LDL receptor-related protein 4) autoantibodies in Italian patients with myasthenia gravis","volume":"10","author":"Marino","year":"2015","journal-title":"PLoS ONE"},{"issue":"5-6","key":"10.1016\/bs.irn.2025.04.024_bib101","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/bs.irn.2025.04.024_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2022.577850","article-title":"The clinical need for clustered AChR cell-based assay testing of seronegative MG","volume":"367","author":"Masi","year":"2022","journal-title":"Journal of Neuroimmunology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib103","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cccn.2004.05.008","article-title":"Muscle-specific receptor tyrosine kinase autoantibodies--a new immunoprecipitation assay","volume":"348","author":"Matthews","year":"2004","journal-title":"Clinica Chimica Acta; International Journal of Clinical Chemistry"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib104","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.20061","article-title":"Detection and characterization of MuSK antibodies in seronegative myasthenia gravis","volume":"55","author":"McConville","year":"2004","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/imr.12821","article-title":"Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies","volume":"292","author":"Meffre","year":"2019","journal-title":"Immunological Reviews"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib106","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/ene.15565","article-title":"Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal","volume":"30","author":"Meisel","year":"2023","journal-title":"European Journal of Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib107","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle autoantibodies in myasthenia gravis: Beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Review of Clinical Immunology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib108","first-page":"204","article-title":"The role of IgG4 as blocking antibodies in asthmatics and in bee keepers","volume":"77","author":"Nakagawa","year":"1985","journal-title":"International Archives of Allergy and Applied Immunology"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib109","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: Quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2025.04.024_bib110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3181\/00379727-105-26050","article-title":"Changes in serum complement activity in patients with myasthenia gravis","volume":"105","author":"Nastuk","year":"1960","journal-title":"Proceedings of the Society for Experimental Biology and Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib111","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1042\/bst0300341","article-title":"Novartis medal lecture. Antibodies: A paradigm for the evolution of molecular recognition","volume":"30","author":"Neuberger","year":"2002","journal-title":"Biochemical Society Transactions"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.024_bib112","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJM197802232980815","article-title":"Plasmapheresis for myasthenia gravis","volume":"298","author":"Newsom-Davis","year":"1978","journal-title":"The New England Journal of Medicine"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib113","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1254\/jphs.94.1","article-title":"Three-finger alpha-neurotoxins and the nicotinic acetylcholine receptor, forty years on","volume":"94","author":"Nirthanan","year":"2004","journal-title":"Journal of Pharmacological Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/mus.880030412","article-title":"Measurement of acetylcholine receptor and anti-receptor antibodies by ELISA","volume":"3","author":"Norcross","year":"1980","journal-title":"Muscle & Nerve"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib116","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nri3795","article-title":"The generation of antibody-secreting plasma cells","volume":"15","author":"Nutt","year":"2015","journal-title":"Nature Reviews. Immunology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib117","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1212\/WNL.30.5.543","article-title":"Myasthenia gravis: Antibodies to acetylcholine receptor with human and rat antigens","volume":"30","author":"Oda","year":"1980","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib118","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"European Journal of Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib119","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"Journal of the Neurological Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0022-510X(85)90144-3","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis: Part 3. The effect of thymectomy","volume":"69","author":"Oosterhuis","year":"1985","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1016\/bs.irn.2025.04.024_bib121","doi-asserted-by":"crossref","DOI":"10.1038\/srep13928","article-title":"Collagen Q and anti-MuSK autoantibody competitively suppress agrin\/LRP4\/MuSK signaling","volume":"5","author":"Otsuka","year":"2015","journal-title":"Scientific Reports"},{"issue":"3-4","key":"10.1016\/bs.irn.2025.04.024_bib122","first-page":"169","article-title":"Range of normal serum immunoglobulin (IgG, IgA and IgM) values in Nigerians","volume":"13","author":"Oyeyinka","year":"1984","journal-title":"African Journal of Medicine and Medical Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib123","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0193723","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features","volume":"13","author":"Park","year":"2018","journal-title":"PLoS ONE"},{"issue":"4088","key":"10.1016\/bs.irn.2025.04.024_bib124","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune response to acetylcholine receptor","volume":"180","author":"Patrick","year":"1973","journal-title":"Science (New York, NY)"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib125","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2015.1444","article-title":"Clinical utility of acetylcholine receptor antibody testing in ocular myasthenia gravis","volume":"72","author":"Peeler","year":"2015","journal-title":"JAMA Neurology"},{"key":"10.1016\/bs.irn.2025.04.024_bib126","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1749-6632.1976.tb47697.x","article-title":"Antibodies to acetylcholine receptors in rabbits: Immunochemical and electrophysiological studies","volume":"274","author":"Penn","year":"1976","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib127","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"Journal of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib128","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","article-title":"Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology","volume":"146","author":"Pham","year":"2023","journal-title":"Acta Neuropathologica"},{"issue":"6","key":"10.1016\/bs.irn.2025.04.024_bib129","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.coi.2011.10.007","article-title":"B cells and autoimmunity","volume":"23","author":"Pillai","year":"2011","journal-title":"Current Opinion in Immunology"},{"issue":"6585","key":"10.1016\/bs.irn.2025.04.024_bib130","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/381751a0","article-title":"Clonal selection and learning in the antibody system","volume":"381","author":"Rajewsky","year":"1996","journal-title":"Nature"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.024_bib131","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41577-023-00871-z","article-title":"The unique properties of IgG4 and its roles in health and disease","volume":"23","author":"Rispens","year":"2023","journal-title":"Nature Reviews. Immunology"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib132","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mus.25438","article-title":"Agrin and Low-density lipoprotein-receptor related protein-4 antibodies in amyotrophic lateral sclerosis patients","volume":"55","author":"Rivner","year":"2017","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib133","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clinical and Experimental Immunology"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.024_bib134","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00415-011-6344-y","article-title":"Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis","volume":"259","author":"Romi","year":"2012","journal-title":"Journal of Neurology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.024_bib135","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"R\u00f8nager","year":"2001","journal-title":"Artificial Organs"},{"key":"10.1016\/bs.irn.2025.04.024_bib136","doi-asserted-by":"crossref","DOI":"10.1007\/s00401-022-02493-6","article-title":"Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities","author":"Rose","year":"2022","journal-title":"Acta Neuropathologica"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib137","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1084\/jem.20042321","article-title":"Impaired early B cell tolerance in patients with rheumatoid arthritis","volume":"201","author":"Samuels","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib138","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle & Nerve"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.024_bib139","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1212\/01.WNL.0000065882.63904.53","article-title":"Clinical aspects of MuSK antibody positive seronegative MG","volume":"60","author":"Sanders","year":"2003","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1212\/CPJ.0000000000000551","article-title":"Signs heralding appearance of thymomas after extended thymectomy for myasthenia gravis","volume":"9","author":"Santos","year":"2019","journal-title":"Neurology. Clinical Practice"},{"issue":"11","key":"10.1016\/bs.irn.2025.04.024_bib141","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/0019-2791(70)90054-6","article-title":"Haptenated bacteriophage in the assay of antibody quantity and affinity: Maturation of an immune response","volume":"7","author":"Sarvas","year":"1970","journal-title":"Immunochemistry"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14350-8","article-title":"Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient","volume":"7","author":"Saxena","year":"2017","journal-title":"Scientific Reports"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.024_bib143","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/WNL.31.8.935","article-title":"Acetylcholine receptor antibody synthesis by thymic lymphocytes: Correlation with thymic histology","volume":"31","author":"Scadding","year":"1981","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib144","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0165-5728(94)90129-5","article-title":"Anti-acetylcholine receptor (AChR) antibodies measurement in myasthenia gravis: The use of cell line TE671 as a source of AChR antigen","volume":"51","author":"Somnier","year":"1994","journal-title":"Journal of Neuroimmunology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib145","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and MuSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurology\u00ae Neuroimmunology & Neuroinflammation"},{"issue":"8","key":"10.1016\/bs.irn.2025.04.024_bib146","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.4049\/jimmunol.1801295","article-title":"Autoantibodies against neurologic antigens in nonneurologic autoimmunity","volume":"202","author":"Stathopoulos","year":"2019","journal-title":"Journal of Immunology"},{"issue":"17","key":"10.1016\/bs.irn.2025.04.024_bib147","doi-asserted-by":"crossref","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/bs.irn.2025.04.024_bib148","doi-asserted-by":"crossref","unstructured":"Strauss, A. J., Seegal, K. C.,\u00a0Hsu,\u00a0P. M., Burkholder,\u00a0W. L., & Nastuk, K. E. (1960). Osserman Proceedings of the Society for Experimental Biology and Medicine. strauss-et-al-1960-immunofluorescence-demonstration-of-a-muscle-binding-complement-fixing-serum-globulin-fraction-in.pdf.","DOI":"10.3181\/00379727-105-26051"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib149","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/practneurol-2015-001126","article-title":"Myasthenia gravis: Association of British Neurologists\u2019 management guidelines","volume":"15","author":"Sussman","year":"2015","journal-title":"Practical Neurology"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib150","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jneuroim.2005.08.017","article-title":"Novel autoantibodies to a voltage-gated potassium channel Kv1. 4 in a severe form of myasthenia gravis","volume":"170","author":"Suzuki","year":"2005","journal-title":"Journal of Neuroimmunology"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib151","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/ane.12271","article-title":"Antititin antibody in early\u2010and late\u2010onset myasthenia gravis","volume":"130","author":"Szczudlik","year":"2014","journal-title":"Acta Neurologica Scandinavica"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.024_bib152","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127167","article-title":"Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients","volume":"4","author":"Takata","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/bs.irn.2025.04.024_bib153","series-title":"Encyclopedia of immunobiology","first-page":"15","article-title":"IgG structure and function","author":"Thomson","year":"2016"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib154","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1084\/jem.177.4.1009","article-title":"Receptor editing in self-reactive bone marrow B cells","volume":"177","author":"Tiegs","year":"1993","journal-title":"The Journal of Experimental Medicine"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib155","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.410100506","article-title":"Humoral immunity in myasthenia gravis: Biochemical characterization of acquired antireceptor antibodies and clinical correlations","volume":"10","author":"Tindall","year":"1981","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"key":"10.1016\/bs.irn.2025.04.024_bib156","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1749-6632.1981.tb33741.x","article-title":"Humoral immunity in myasthenia gravis: Clinical correlations of anti-receptor antibody avidity and titer","volume":"377","author":"Tindall","year":"1981","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib157","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1073\/pnas.71.10.4027","article-title":"Evidence for somatic generation of antibody diversity","volume":"71","author":"Tonegawa","year":"1974","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5909","key":"10.1016\/bs.irn.2025.04.024_bib158","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/302575a0","article-title":"Somatic generation of antibody diversity","volume":"302","author":"Tonegawa","year":"1983","journal-title":"Nature"},{"key":"10.1016\/bs.irn.2025.04.024_bib159","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jim.2018.06.016","article-title":"Immunostick ELISA for rapid and easy diagnosis of myasthenia gravis","volume":"460","author":"Trakas","year":"2018","journal-title":"Journal of Immunological Methods"},{"issue":"4 Pt B","key":"10.1016\/bs.irn.2025.04.024_bib160","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.bbadis.2017.07.038","article-title":"On the role of IgG4 in inflammatory conditions: Lessons for IgG4-related disease","volume":"1864","author":"Trampert","year":"2018","journal-title":"Biochimica et biophysica acta Molecular basis of disease"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib161","first-page":"62","article-title":"Arthrogryposis and maternal myasthenia gravis. Risk of recurrence","volume":"147","author":"Tranchant","year":"1991","journal-title":"Revue Neurologique"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib162","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.hemonc.2017.04.001","article-title":"Myasthenia gravis after allogeneic bone marrow transplantation: A case report and literature review","volume":"12","author":"Tsutsumi","year":"2019","journal-title":"Hematology\/Oncology and Stem Cell Therapy"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib163","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/acn3.26","article-title":"LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients","volume":"1","author":"Tzartos","year":"2014","journal-title":"Annals of Clinical and Translational Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib164","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1073\/pnas.79.1.188","article-title":"Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies","volume":"79","author":"Tzartos","year":"1982","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"5844","key":"10.1016\/bs.irn.2025.04.024_bib165","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science (New York, N.Y)"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib166","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jaci.2012.08.037","article-title":"Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE","volume":"131","author":"Varga","year":"2013","journal-title":"The Journal of Allergy and Clinical Immunology"},{"issue":"13","key":"10.1016\/bs.irn.2025.04.024_bib167","article-title":"Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis","volume":"118","author":"Vergoossen","year":"2021","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib168","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and Low-density lipoprotein-receptor related protein-4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/bs.irn.2025.04.024_bib169","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00520","article-title":"IgG subclasses and allotypes: From structure to effector functions","volume":"5","author":"Vidarsson","year":"2014","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib170","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1515\/cclm-2023-0205","article-title":"Acetylcholine receptor and muscle-specific tyrosine kinase antibodies detection: Is it time for a change?","volume":"61","author":"Villalta","year":"2023","journal-title":"Clinical Chemistry and Laboratory Medicine: CCLM\/FESCC"},{"issue":"23","key":"10.1016\/bs.irn.2025.04.024_bib171","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1046\/j.1432-1033.2000.01785.x","article-title":"Molecular targets for autoimmune and genetic disorders of neuromuscular transmission","volume":"267","author":"Vincent","year":"2000","journal-title":"European Journal of Biochemistry\/FEBS"},{"issue":"8966","key":"10.1016\/bs.irn.2025.04.024_bib172","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0140-6736(95)92652-6","article-title":"Arthrogryposis multiplex congenita with maternal autoantibodies specific for a fetal antigen","volume":"346","author":"Vincent","year":"1995","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/bs.irn.2025.04.024_bib173","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nature Reviews. Immunology"},{"issue":"9","key":"10.1016\/bs.irn.2025.04.024_bib174","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1136\/jnnp-2021-326480","article-title":"Using AChR antibody titres to predict treatment responses in myasthenia gravis","volume":"92","author":"Vincent","year":"2021","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"7","key":"10.1016\/bs.irn.2025.04.024_bib175","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp.43.7.590","article-title":"Anti-acetylcholine receptor antibodies","volume":"43","author":"Vincent","year":"1980","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib176","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clinical and Experimental Immunology"},{"issue":"12","key":"10.1016\/bs.irn.2025.04.024_bib177","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1136\/jnnp.48.12.1246","article-title":"Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: Results in 153 validated cases and 2967 diagnostic assays","volume":"48","author":"Vincent","year":"1985","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib178","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evidence"},{"issue":"3","key":"10.1016\/bs.irn.2025.04.024_bib179","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1432-1033.1985.tb09054.x","article-title":"Monoclonal antibodies to torpedo acetylcholine receptor. Characterisation of antigenic determinants within the cholinergic binding site","volume":"150","author":"Whiting","year":"1985","journal-title":"European Journal of Biochemistry\/FEBS"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib180","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1212\/WNL.36.5.612","article-title":"Myasthenia gravis","volume":"36","author":"Whiting","year":"1986","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2025.04.024_bib181","first-page":"97","article-title":"Cell types required for anti-acetylcholine receptor antibody synthesis by cultured thymocytes and blood lymphocytes in myasthenia gravis","volume":"58","author":"Willcox","year":"1984","journal-title":"Clinical and Experimental Immunology"},{"issue":"6-8","key":"10.1016\/bs.irn.2025.04.024_bib182","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.mod.2012.09.004","article-title":"The neuromuscular junction: Selective remodeling of synaptic regulators at the nerve\/muscle interface","volume":"130","author":"Witzemann","year":"2013","journal-title":"Mechanisms of Development"},{"issue":"1-2","key":"10.1016\/bs.irn.2025.04.024_bib183","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jns.2010.10.023","article-title":"Non-radioactive serological diagnosis of myasthenia gravis and clinical features of patients from Tianjin, China","volume":"301","author":"Yang","year":"2011","journal-title":"Journal of the Neurological Sciences"},{"issue":"2","key":"10.1016\/bs.irn.2025.04.024_bib184","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/mus.25973","article-title":"B cells in the pathophysiology of myasthenia gravis","volume":"57","author":"Yi","year":"2018","journal-title":"Muscle & Nerve"},{"key":"10.1016\/bs.irn.2025.04.024_bib185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.951385","article-title":"B cells in the balance: Offsetting self-reactivity avoidance with protection against foreign","volume":"13","author":"Young","year":"2022","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/bs.irn.2025.04.024_bib186","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012463","article-title":"Characterization of LRP4\/agrin antibodies from a patient with myasthenia gravis","author":"Yu","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/bs.irn.2025.04.024_bib187","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1084\/jem.20042251","article-title":"Defective B cell tolerance checkpoints in systemic lupus erythematosus","volume":"201","author":"Yurasov","year":"2005","journal-title":"The Journal of Experimental Medicine"},{"issue":"4","key":"10.1016\/bs.irn.2025.04.024_bib188","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2025.04.024_bib189","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"Journal of Autoimmunity"}],"container-title":["International Review of Neurobiology","Myasthenia Gravis: Part A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007477422500039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S007477422500039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T09:44:25Z","timestamp":1753263865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S007477422500039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443429835"],"references-count":189,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2025.04.024","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}